UNSPSC 51144016: Morforex

This classification denotes an anorexiant, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) O9J6ITY8UX. European Medicines Agency schedules Morforex in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09066MIG. Morforex generally arises in the molecular formula C15H24N2O. The term MORFOREX is an International Non-Proprietary Name or INN. MORFOREX is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix.

Most nations, for tariff and trade purposes, schedule morforex under HS 29349990 and SITC 51579. As of Q4 2014, MORFOREX remains US FDA's Preferred Term for this commodity. Morforex bears US NLM identifiers UMLS ID C1881900 and NCI Concept Code C66195. SMILES: O1CCN(CCNC(CC2CCCCC2)C)CC1.

UNSPSC 51144016 Morforex is a Commodity code under which state and local governments procure naloxone, drug deactivation systems, generic pharmaceuticals, and over-the-counter medications to support public health initiatives, emergency response programs, and health benefit administration. Recent opportunities show purchasing authorities acquiring these products for community health building distribution, cooperative pharmaceutical supply networks, and therapeutic pharmacy programs that bypass traditional pharmacy benefit manager channels. The work spans single-jurisdiction procurements through county health departments and multistate cooperative purchasing vehicles that aggregate demand across participating state and local agencies. Issuing bodies include county health departments, state health and human services commissions, and multistate cooperative purchasing alliances that coordinate procurement across multiple participating jurisdictions.

Recent activity concentrates in Florida and Minnesota with emerging Texas engagement. Seminole County, Florida released IFB 60459723LAS on June 30, 2026, seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries and a response deadline of July 26, 2023. The Minnesota Department of Administration's Office of State Procurement, administering the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), issued RFP S1070000015802 on January 20, 2026, to establish contracts for generic multi-source pharmaceuticals and OTC products across participating state and local facilities including Oregon, with proposals due March 26, 2026, and awarded vendors providing products to authorized wholesalers effective July 1, 2026. The Texas Health and Human Services Commission issued RFI HHS0017013 on April 3, 2026, to gather vendor capabilities for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program, seeking information from vendors about direct contracting capacity outside traditional pharmacy benefit manager arrangements.